Novo Nordisk Korea will join hands with Kakao Healthcare to build a digital healthcare ecosystem for..

Novo Nordisk Korea will join hands with Kakao Healthcare to build a digital healthcare ecosystem for obese and diabetic patients.

Novo Nordisk Korea announced on the 3rd that it signed a strategic business agreement (MOU) with Kakao Healthcare on the 2nd. The previous day’s signing ceremony was attended by key officials from both companies, including Casper Rossille Poulsen, CEO of Novo Nordisk Pharmaceutical, and Hwang Hee, CEO of Kakao Healthcare.

Through this collaboration, the two companies plan to use digital technology to create a sustainable treatment environment that can improve the treatment experience for obese and diabetic patients and lead to better treatment outcomes.

This is the second business agreement between the two companies after 2023. The last business agreement was to provide a medication management solution for diabetic patients by linking “Maliya,” a smart cap for Novo Nordisk Pharmaceutical’s insulin flex touch pen, with Kakao Healthcare’s pasta.

This agreement is meaningful in that it has extended cooperation between the two companies to the area of obesity. It promotes collaboration to provide patient-centered digital solutions corresponding to the unmet medical needs of obese and diabetic patients in Korea.

First, in the area of obesity, we will promote specific collaboration with the aim of providing ▲ patient-specific digital support programs ▲ providing solutions for additional treatment effects and quality of life.

In particular, Korea Novo Nordisk plans to connect the function of the patient support program provided by Novo Nordisk to its obesity treatment patients to Kakao Healthcare’s pasta app to help obese patients manage their long-term weight and comprehensive health.

In the field of diabetes, we aimed to develop and cooperate with digital solutions to improve disease awareness. The specific results of the agreement are expected to be disclosed as early as this year.

“Obesity and diabetes are chronic diseases that cause serious comorbidities if left unattended, putting a huge burden on individuals and society,” said Casper Rossille Poulsen, CEO of Novo Nordisk Pharmaceutical. “We expect that innovation in domestic patient support will accelerate through cooperation between Novo Nordisk, which has been dedicated to diabetes and obesity over more than 100 years, and Kakao Healthcare, which represents digital healthcare in Korea.”

Hwang Hee, CEO of Kakao Healthcare, said, “We expect our know-how, which has led to positive changes in the patient’s health journey based on various technologies such as AI and big data, to play a big role in expanding patient-centered digital healthcare globally with Novo Nordisk.”